European Heart Journal Advance Access originally published online on June 21, 2008
European Heart Journal 2008 29(18):2202-2211; doi:10.1093/eurheartj/ehn287
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
1 Division of Cardiology, University of Florida College of Medicine at Shands Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA
2 Department of Medicine, Tokai University School of Medicine, Isehara, Japan
3 Jacksonville Transplant Center, Shands Jacksonville, Jacksonville, FL, USA
Received 26 February 2008; revised 2 June 2008; accepted 5 June 2008; online publish-ahead-of-print 21 June 2008.
* Corresponding author. Tel: +1 904 244 3933, Fax: +1 904 244 3102, Email: dominick.angiolillo{at}jax.ufl.edu
See page 2191 for the editorial comment on this article (doi:10.1093/eurheartj/ehn367)
Aims: Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y12 receptor blockade. Whether inhibition of P2Y12 signalling can be enhanced by adjunctive treatment with cilostazol in T2DM patients is unknown. The aim of this pilot study was to assess the functional impact of cilostazol in T2DM patients on standard aspirin and clopidogrel treatment.
Methods and results: This was a prospective, double-blind, double-dummy, placebo-controlled, randomized, cross-over platelet function study. T2DM patients on dual antiplatelet therapy were assigned to receive cilostazol 100 mg or placebo twice daily for 14 days and afterwards crossed-over treatment assignments for another 14 days. Platelet function was performed at three time points: at baseline, 14 days after randomization, and 14 days after treatment cross-over. The P2Y12 reactivity index, determined through flow cytometric assessment of the phosphorylation status of the vasodilator-stimulated phosphoprotein, was the primary endpoint measure. In addition to this flow cytometric evaluation, light transmittance aggregometry and VerifyNow testing were performed. A total of 25 T2DM patients were randomized; five patients discontinued treatment due to side effects. The P2Y12 reactivity index was significantly lower following cilostazol treatment compared with placebo (36.3 ± 20 vs. 59.9 ± 16%; P = 0.0002). All other P2Y12-specific functional assessments showed enhanced inhibition of this signalling pathway following treatment with cilostazol.
Conclusion: Adjunctive treatment with cilostazol in T2DM patients on standard dual antiplatelet therapy enhances inhibition of platelet P2Y12 signalling.
Key Words: Diabetes mellitus • Platelets • Thrombosis • Clopidogrel • Cilostazol
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Diabetic atherothrombosis: helpful adjunctive therapy
- James H. Chesebro
EHJ 2008 29: 2191-2192.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  D. J. Angiolillo Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions Diabetes Care, April 1, 2009; 32(4): 531 - 540. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology Eur. Heart J., February 2, 2009; 30(4): 426 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Chhatriwalla and D. L. Bhatt Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely Circ Cardiovasc Interv, December 1, 2008; 1(3): 217 - 225. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bhatt Resisting the Temptation to Oversimplify Antiplatelet Resistance J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 660 - 662. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Chesebro Diabetic atherothrombosis: helpful adjunctive therapy Eur. Heart J., September 2, 2008; 29(18): 2191 - 2192. [Full Text] [PDF]
|
|